Skip over navigation
View all faculty »

Michael Hecht

Research Focus


Research in the Hecht group focuses in two areas: Synthetic Biology and Alzheimer's Disease. Although these fields may seem quite different, they explore two facets of the same problem. Synthetic biology requires an ability to devise novel proteins, which ultimately comes down to designing amino acid sequences that fold into a specific 3-dimensional structure. Conversely, probing the molecular underpinnings of Alzheimer’s disease requires an understanding of how sequences fail to fold into globular protein structures, but instead misfold into oligomeric or fibrillar structures.

(1) Synthetic Biology: From Protein Design to Artificial Genomes. Research in the life sciences has advanced to a point where we can consider the possibility of sustaining life using molecular parts that did not evolve in nature, but which are designed and synthesized in the laboratory. Although myriad forms of life evolved over billions of years, the biosphere has sampled only a miniscule fraction of the possible genes and proteins that could be constructed. Are these biologically selected sequences somehow special? Or is it possible to sustain life using a ‘molecular parts kit’ designed de novo? Our research addresses these questions by going beyond the limited collection sampled by nature; beyond what exists (or existed in the past) in living systems. We explore artificial biological information (genes) and macromolecules (proteins) to probe the ability of these novel genes and proteins to perform biochemical activities, and ultimately to sustain life.
Our work in synthetic biology is enabled by methods we developed to design and construct combinatorial libraries of novel proteins that fold into stable structures. With collections of millions of well-folded de novo proteins, we explore a range of questions at the interface of chemistry and biology For example, we can test the chemical and structural requirements for protein design, while also probing the biological implications of proteome design. Moreover, because our designed proteins are expressed from synthetic genes cloned into living cells, we can begin to construct ‘artificial genomes’ comprising sequences (genes and proteins) that never existed before in biology. Recent results show that these novel macromolecules – which bear no resemblance to natural genes or proteins – can provide some of the functions necessary to enable cell growth. Thus, the molecular ‘parts kit’ for life need not be limited to genes and proteins derived nature; and artificial genomes capable of sustaining life may soon be within reach.

(2) Alzheimer's disease: Molecular Underpinnings and the Search for New Therapeutics. One hundred years ago Alois Alzheimer observed a relationship between cognitive impairment and the presence of plaque in the brains of patients suffering from the disease that now bears his name. The plaque was subsequently shown to be composed primarily of a protein fragment, or peptide, called Aβ. It is now understood that aggregation of Aβ into oligomers and amyloid fibrils plays a central role in the molecular etiology of Alzheimer's disease (AD). Our work on AD aims to address two questions: (i) What causes Aβ aggregation? and (ii) Can we block it? Our research on the causes of Aβ aggregation focuses on the relationship between the sequence of Aβ and its propensity to aggregate. We constructed collections of mutant Aβ peptides and characterized which features of the sequence enhance or prevent aggregation. Our search for Alzheimer's therapeutics relies on a novel high throughput screen for compounds that inhibit aggregation of the A-beta peptide. Several promising compounds have been isolated, and are being tested in animal models.

NMR Structure
NMR Structure of a 4-helix bundle protein designed de novo. Hydrophobic residues are shown in yellow and polar residues are red.

Selected Recent Publications


  • Kamtekar S, Schiffer JM, Xiong H, Babik JM & Hecht MH (1993) Protein Design by Binary Patterning of Polar and Non-Polar Amino Acids. Science 262, 1680-1685.
  • Moffet DA, Certain LK, Smith AJ, Kessel AJ, Beckwith KA & Hecht MH (2000) Peroxidase Activity in Heme Proteins Derived From a Designed Combinatorial Library. J. Am. Chem. Soc. 122, 7612-7613.
  • Brown CL, Aksay IA, Saville DA, & Hecht MH (2002) Template-Directed Assembly of a De Novo Designed Protein. J. Am. Chem. Soc. 124, 6846-6848
  • Wei Y, Liu T, Sazinsky SL, Moffet DA, Pelczer I, & Hecht MH (2003) Stably Folded De Novo Proteins From a Designed Combinatorial Library. Protein Science 12, 92-102.
  • Wei Y, Kim S, Fela D, Baum J, & Hecht MH. (2003) Solution Structure of a De Novo Protein from a Designed Combinatorial Library. Proc. Natl Acad. Sci.(USA) 100, 13270-13273.
  • Wei Y & Hecht MH. (2004) Enzyme-like Proteins from an Unselected Library of Designed Amino Acid Sequences. Protein Engineering, Design& Selection (PEDS) 17, 67-75.
  • Hecht MH, Das A, Go A, Bradley LH, Wei Y (2004) De Novo Proteins from Designed Combinatorial Libraries Protein Science 13, 1711-1723.
  • Go A, Kim S, & Baum J. & Hecht MH, (2008) Structure and Dynamics of De novo Proteins from a Designed Superfamily of 4-Helix Bundles Protein Science 17, 821-832.
  • Patel S, Bradley LH, Jinadasa S, Hecht MH. (2009) Cofactor Binding and Enzymatic Activity in an Unevolved Superfamily of De Novo Designed 4-Helix Bundle Proteins, Protein Science 18, 1388-1400.
  • Fisher MA, McKinley KL, Bradley LH, Viola SR & Hecht MH (2011) De Novo Designed Proteins From a Library of Artificial Sequences Function in Escherichia Coli and Enable Cell Growth. PLoS ONE 6(1): e15364. doi:10.1371/journal.pone.0015364
  • Das A, Wei Y, Pelczer I & Hecht MH (2011) Binding of Small Molecules to Cavity Forming Mutants of a De Novo Designed Protein. Protein Science 20, 702—711


  • Wurth C, Guimard NK, & Hecht MH. (2002) Mutations that Reduce Aggregation of the Alzheimer’s Aß42 Peptide: An Unbiased Search for the Sequence Determinants of Aß Amyloidogenesis. J. Molec. Biology 319, 1279-1290
  • Kim W, & Hecht MH (2005) Mutagenesis of the Carboxy-Terminal Residues of the Alzheimer’s Peptide: Sequence Determinants of Enhanced Amyloidogenicity of Aβ42 Relative to Aβ40. J. Biological Chemistry 280, 35069-35076.
  • Kim W, Kim Y, Min J, Kim DJ, Chang Y-T & Hecht MH (2006) A High Throughput Screen for Compounds that Inhibit Aggregation of the Alzheimer’s Peptide. ACS Chemical Biology 1, 461-469.
  • Kim W, Hecht MH (2006) Generic Hydrophobic Residues are Sufficient to Promote Aggregation of the Alzheimer’s Aß42 Peptide. Proc. Natl Acad. Sci.(USA) 103, 15824-15829.
  • Kim W, Hecht MH (2008) Mutations Enhance the Aggregation Propensity of the Alzheimer’s Aß Peptide J. Molec. Biology. 377 565-574.
  • Chen J, Armstrong AH, Koehler AN & Hecht MH (2010) Small Molecule Microarrays Enable the Discovery of Compounds that Bind the Alzheimer’s Aß Peptide and Reduce Cytotoxicity. J. Am. Chem. Soc. 132, 17015-17022.
  • Olzscha H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, Tartaglia GG, Vendruscolo M, Hayer-Hartl M, Hartl FU, Vabulas RM (2011) Amyloid-like Aggregates Sequester Numerous Metastable Proteins with Essential Cellular Functions. Cell 144, 67-78.

Michael Hecht

Hecht Lab Webpage
Frick Laboratory, 330
Phone: 609-258-2901

Faculty Assistant:
Kuri Chacko
Frick Laboratory, 389
Phone: 609-258-3924